Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
Authors:
- 26 September 2014
- journal article
- review article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 40 (2) , 259-267
Abstract
Large 'real world' studies demonstrating the limited effectiveness and slow onset of clinical response associated with our existing antidepressant medications has highlighted the need for the development of new therapeutic strategies for major depression and other mood disorders. Yet, despite intense research efforts, the field has had little success in developing antidepressant treatments with fundamentally novel mechanisms of action over the past six decades, leaving the field wary and skeptical about any new developments. However, a series of relatively small proof-of-concept studies conducted over the last 15 years has gradually gained great interest by providing strong evidence that a unique, rapid onset of sustained, but still temporally limited, antidepressant effects can be achieved with a single administration of ketamine. We are now left with several questions regarding the true clinical meaningfulness of the findings and the mechanisms underlying the antidepressant action. In this Circumspectives piece, Dr Sanacora and Dr Schatzberg share their opinions on these issues and discuss paths to move the field forward.Keywords
This publication has 92 references indexed in Scilit:
- Antidepressant Augmentation Using theN-Methyl-d-Aspartate Antagonist MemantineThe Journal of Clinical Psychiatry, 2013
- Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brainProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2013
- Involvement of the GluN2A and GluN2B Subunits in Synaptic and Extrasynaptic N-methyl-d-aspartate Receptor Function and Neuronal ExcitotoxicityJournal of Biological Chemistry, 2013
- Acute Suppression of Spontaneous Neurotransmission Drives Synaptic PotentiationThe Journal of Neuroscience, 2013
- Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humansMolecular Psychiatry, 2013
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responsesNature, 2011
- Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant DepressionBiological Psychiatry, 2010
- Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid ReceptorsBiological Psychiatry, 2008
- Ketamine2008
- Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid.The Journal of Pharmacology and Experimental Therapeutics, 1993